Shares of DBV Technologies S.A. (NASDAQ:DBVT) were up 6.8% on Thursday . The stock traded as high as $6.01 and last traded at $5.96. Approximately 318 shares traded hands during trading, a decline of 100% from the average daily volume of 678,058 shares. The stock had previously closed at $5.58.
Several research analysts have weighed in on DBVT shares. Citigroup raised their price objective on shares of DBV Technologies from $4.00 to $8.00 in a report on Friday, January 15th. SVB Leerink reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, March 12th. Zacks Investment Research raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, April 2nd. Societe Generale lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, January 22nd. Finally, The Goldman Sachs Group lifted their price target on shares of DBV Technologies from $4.00 to $7.00 in a report on Monday, January 18th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $7.11.
The stock has a market capitalization of $657.04 million, a P/E ratio of -2.56 and a beta of 2.91. The company’s 50-day moving average is $5.47 and its two-hundred day moving average is $3.66. The company has a current ratio of 4.28, a quick ratio of 4.22 and a debt-to-equity ratio of 0.08.
About DBV Technologies (NASDAQ:DBVT)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
Recommended Story: Discover Your Risk Tolerance
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.